HA-Head binds to sialic acidity from the host cell receptor when the influenza pathogen makes connection with the host surface area. many pandemics, including H1N1 in 1918, where about 500 million people world-wide were infected, accounting for one-third from the worlds inhabitants at the proper period, with at least 50 million fatalities; H2N2 in 1957, about 1.1 million global fatalities; and H3N2 in 1968, producing a total around 1 million fatalities, those aged 65 and older [2] mainly. This year’s 2009 H1N1 pandemic triggered 151,700-575,400 fatalities world-wide [2]. Furthermore to individual influenza viruses, extremely pathogenic avian influenza also poses a potential threat to human health. In 1997, human infection with H5N1 was first reported in Hong Kong, and in 2003, another one was also reported in Hong Kong. So far, 861 confirmed H5N1 infections worldwide were reported to World Health Organization (WHO), including 455 deaths, with a fatality rate of 53% [[3], [4], [5]]. In 2013, H7N9 was detected in China, with 1568 confirmed infections globally as of February 2020, with a fatality rate of nearly 40% [4], [6]. In addition to the above influenza pandemics, the spread of seasonal influenza can also pose a major threat to human health. According to the WHO [1], worldwide, about 3 million to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths are associated with seasonal influenza each year [1]. People with seasonal influenza can suffer from fever, cough, runny nose and other symptoms, and serious outcomes of influenza infection can result in death [1]. Therefore, control and prevention of the disease are vitally important, and vaccination is currently the most effective way to combat influenza virus [1]. Hemagglutinin (HA) of the trimer and neuraminidase (NA) of the tetramer are two glycoproteins on the IAV and IBV surface. They play an important role in the process of virus infection and escape, each with high variability owing to adaption to environmental changes and host immune escape response (Fig.?1 A) [7,8]. According to genetic and antigenic variation, the current 18 subtypes of IAV HA (H1CH18) are divided into group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18) and group 2 (H3, H4, H7, H10, H14, and H15), while IAV of NA has 11 subtypes (N1CN11). IBV consists mainly of two lineages, Victoria and Yamagata [[9], [10], [11]]. HA consists of three single HA0 protein precursors, which form stable HA1 and HA2 linked by disulfide bonds during maturation [12,13]. HA-Head is composed of HA1 residues, and HA-Stalk GYKI53655 Hydrochloride is composed of partial residues of HA1 and complete HA2 (Fig.?1B). HA-Head binds to sialic acid of the host cell receptor when the influenza virus makes contact with the host surface. The cell membrane then envelops the virus to form vesicles. At low pH, HA-Stalk-mediated virus fuses with host endosomal membrane and releases genetic material into the host to be replicated [7,14,13,12,15]. The relatively less abundant NA, the main function of which is to hydrolyze glycoside bonds between sialic acid and host glycoproteins, helps mature influenza viruses escape from host cells (Fig.?2 ) [7,16,10]. Open in a separate window Fig.?1 The structure of glycoproteins.A. The structure of the virus, HA and NA. B. Comparison of Head and Stalk with HA1 and HA2. Open in Rabbit Polyclonal to MEF2C a separate window Fig.?2 An overview of the process of virus infection, replication and release. A, B The virus binds to host sialic acid by HA and enters the cell by endocytosis; NA enhances the HA-mediated membrane fusion process, facilitating virus entry. C, D The low pH of the endosome causes the viral envelope to fuse with the endosomal membrane, and the viral genetic material, vRNPs, is released into the cytoplasm. E vRNPs enter the GYKI53655 Hydrochloride nucleus and initiate the transcription process, replicating various viral proteins and RNAs. F, G The synthesized viral components and vRNPs are processed and transported by Golgi bodies and endoplasmic reticulum to complete the assembly of virions on the host cell membrane. H The progeny virus is released. As a biotargeted drug, monoclonal antibodies have been widely studied in the field of anti-infection in recent years, including anti-HIV antibodies 3BNC117, 10-1074 and VRC01, GYKI53655 Hydrochloride which are currently in clinical trials [17,18]; anti-Coronavirus antibodies [19,20]; anti-Ebola antibodies [21,22] and anti-Hendra and Nipah virus antibodies [23]. Getting vaccinated each year is currently the best way to combat the influenza virus. Antibodies produced by vaccination neutralize the corresponding virus, thereby effectively preventing the occurrence of the corresponding subtype influenza pandemic. Nevertheless, this solution can be thwarted by the long production cycle of the vaccine and the high.